Lymphoma-directed conditioning for aggressive lymphoma
Mené sur 84 patients atteints d'un lymphome à cellules B ou à cellules T réfractaire et récidivant, cet essai allemand de phase II évalue l'efficacité de l'ajout du rituximab à un traitement prophylactique standard après une greffe allogénique de cellules souches
Treatment of patients with aggressive B-cell and T-cell lymphomas who relapse or who are refractory after first-line immunochemotherapy is difficult. Although autologous stem-cell transplantation is deemed to be the standard of care for these patients according to the PARMA trial, 1 the CORAL trial 2 showed that even this approach often has a poor outcome, with treatment failure in more than 80% of patients. How best to achieve remission and consolidate treatment with stem-cell transplantation is...
The Lancet Oncology , commentaire, 2013